Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review.
Cancer
Immunomodulation
Macrophages
Radiobiology
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
01
12
2022
accepted:
23
04
2023
medline:
27
11
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Tumor-associated macrophages (TAMs) are the most represented cells of the immune system in the tumor microenvironment (TME). Besides its effects on cancer cells, radiation therapy (RT) can alter TME composition. With this systematic review, we provide a better understanding on how RT can regulate macrophage characterization, namely the M1 antitumor and the M2 protumor polarization, with the aim of describing new effective RT models and exploration of the possibility of integrating radiation with other available therapies. A systematic search in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was carried out in PubMed, Google Scholar, and Scopus. Articles from January 2000 to April 2020 which focus on the role of M1 and M2 macrophages in the response to RT were identified. Of the 304 selected articles, 29 qualitative summary papers were included in our analysis (16 focusing on administration of RT and concomitant systemic molecules, and 13 reporting on RT alone). Based on dose intensity, irradiation was classified into low (low-dose irradiation, LDI; corresponding to less than 1 Gy), moderate (moderate-dose irradiation, MDI; between 1 and 10 Gy), and high (high-dose irradiation, HDI; greater than 10 Gy). While HDI seems to be responsible for induced angiogenesis and accelerated tumor growth through early M2-polarized TAM infiltration, MDI stimulates phagocytosis and local LDI may represent a valid treatment option for possible combination with cancer immunotherapeutic agents. TAMs seem to have an ambivalent role on the efficacy of cancer treatment. Radiation therapy, which exerts its main antitumor activity via cell killing, can in turn interfere with TAM characterization through different modalities. The plasticity of TAMs makes them an attractive target for anticancer therapies and more research should be conducted to explore this potential therapeutic strategy.
Identifiants
pubmed: 37347290
doi: 10.1007/s00066-023-02097-3
pii: 10.1007/s00066-023-02097-3
pmc: PMC10673745
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1173-1190Informations de copyright
© 2023. The Author(s).
Références
Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
Oncotarget. 2017 Jul 12;8(46):80506-80520
pubmed: 29113321
BMC Cancer. 2014 May 10;14:330
pubmed: 24885636
Immunobiology. 2017 Jan;222(1):55-65
pubmed: 26705936
NPJ Breast Cancer. 2016;2:
pubmed: 26998515
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Sci Rep. 2016 Dec 19;6:39190
pubmed: 27991524
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Carcinogenesis. 2016 Mar;37(3):301-313
pubmed: 26785731
Curr Opin Immunol. 2010 Apr;22(2):231-7
pubmed: 20144856
Sci Rep. 2016 Jan 06;6:18765
pubmed: 26735768
Br J Pharmacol. 1992 Dec;107(4):1092-5
pubmed: 1281718
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9
pubmed: 23462419
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):892-900
pubmed: 26530759
Biochim Biophys Acta. 1995 May 24;1271(1):205-9
pubmed: 7599209
Cell Death Dis. 2018 Jun 27;9(7):728
pubmed: 29950610
Gastroenterology. 2016 Jun;150(7):1659-1672.e5
pubmed: 26946344
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
Nat Commun. 2018 Nov 30;9(1):5108
pubmed: 30504836
Cancer Growth Metastasis. 2018 Mar 09;11:1179064418761639
pubmed: 29551910
J Cell Mol Med. 2020 Apr;24(7):3917-3930
pubmed: 32135028
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Pathol. 2009 Mar;174(3):1048-64
pubmed: 19218341
J Natl Cancer Inst. 2015 Feb 20;107(4):
pubmed: 25710962
BMC Cancer. 2015 Aug 08;15:577
pubmed: 26253167
Front Immunol. 2017 Mar 13;8:229
pubmed: 28348554
Comput Biol Chem. 2018 Jun;74:368-378
pubmed: 29615312
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Cancer Immunol Res. 2015 May;3(5):518-25
pubmed: 25716473
FEBS J. 2018 Feb;285(4):680-699
pubmed: 29171156
Sci Adv. 2020 Mar 25;6(13):eaay9789
pubmed: 32232155
Cell Death Differ. 2017 Sep;24(9):1632-1644
pubmed: 28574504
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1034-1043
pubmed: 29485045
Radiat Res. 2009 Feb;171(2):219-24
pubmed: 19267548
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Trends Immunol. 2015 Apr;36(4):229-39
pubmed: 25770924
Cancer Res. 2015 Jul 15;75(14):2788-99
pubmed: 25990221
Neuro Oncol. 2016 Jun;18(6):797-806
pubmed: 26538619
Cancer Res. 2018 Aug 1;78(15):4241-4252
pubmed: 29880480
Immunol Lett. 2014 Jul;160(1):1-10
pubmed: 24698728
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8
pubmed: 25136121
Sci Rep. 2016 Jun 08;6:27548
pubmed: 27271009
PLoS One. 2016 Aug 11;11(8):e0160891
pubmed: 27513864
Gastroenterology. 2019 May;156(7):2056-2072
pubmed: 30660727
J Immunol. 2005 Jan 15;174(2):636-45
pubmed: 15634881
Immunotherapy. 2011 Apr;3(4 Suppl):23-6
pubmed: 21524164
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):499-507
pubmed: 17398016
Int J Oncol. 2013 Jul;43(1):5-12
pubmed: 23673510
J Cell Biochem. 2003 Jan 1;88(1):144-51
pubmed: 12461784
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):913-923
pubmed: 30922944
J Neurooncol. 2020 May;147(3):547-555
pubmed: 32215786
Int J Oncol. 2020 Jun;56(6):1405-1416
pubmed: 32236622
PLoS One. 2012;7(12):e50946
pubmed: 23284651
Radiat Res. 2017 Jan;187(1):50-59
pubmed: 28054838
Cancer Lett. 2019 Aug 1;456:69-79
pubmed: 31055110
Cancer Lett. 2019 Sep 10;459:145-155
pubmed: 31173854
PLoS One. 2012;7(6):e39295
pubmed: 22761754
J Exp Med. 1996 Apr 1;183(4):1323-9
pubmed: 8666890
Lab Invest. 2013 Jul;93(7):844-54
pubmed: 23752129
PLoS One. 2012;7(5):e36928
pubmed: 22629344
Elife. 2016 Oct 03;5:
pubmed: 27692066
Biochem Biophys Res Commun. 2017 Aug 19;490(2):514-520
pubmed: 28624450
Curr Opin Pharmacol. 2017 Aug;35:12-19
pubmed: 28538141
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335026
Prostate. 2004 Aug 1;60(3):178-86
pubmed: 15176047
Oncotarget. 2017 Aug 7;8(42):72597-72612
pubmed: 29069812
In Vivo. 2019 Nov-Dec;33(6):1773-1784
pubmed: 31662502